KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
June 01 2017 - 7:30AM
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today
announced that it will present a corporate overview at the
Jefferies Healthcare Conference on Thursday, June 8, 2017, at 9:30
a.m. EDT in New York City.
A live webcast of the presentation may be
accessed in the Investors section of the Company’s website at
www.kalvista.com. A replay of the webcast will be available on
KalVista’s website for 30 days following the presentation.
About KalVista Pharmaceuticals,
Inc.KalVista Pharmaceuticals, Inc. is a pharmaceuticals
company focused on the discovery, development, and
commercialization of small molecule protease inhibitors for
diseases with significant unmet need. The initial focus is on
inhibitors of plasma kallikrein, which is an important component of
the body’s inflammatory response, and which in excess can lead to
increased vascular permeability, edema and inflammation. KalVista
has developed a proprietary portfolio of novel, small molecule
plasma kallikrein inhibitors initially targeting hereditary
angioedema (HAE) and diabetic macular edema (DME). The Company has
created a structurally diverse portfolio of oral plasma kallikrein
inhibitors from which it plans to select multiple drug candidates
to advance into clinical trials for HAE. The first of this planned
portfolio of programs, KVD818, is currently in a first-in-human
study and additional program candidates are in preclinical
development. KalVista’s most advanced program, an intravitreally
administered plasma kallikrein inhibitor known as KVD001, has
successfully completed its first‑in‑human study in patients with
DME and is being prepared for Phase 2 studies in 2017.
For more information, please visit
www.KalVista.com.
Forward-Looking StatementsThis
press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding
and future clinical trial timing and results. Further information
on potential risk factors that could affect our business and its
financial results are detailed in the definitive proxy statement
filed on October 28, 2016, our most recent Quarterly Report on Form
10-Q, and other reports as filed from time to time with
the Securities and Exchange Commission. We undertake no
obligation to publicly update any forward-looking statement,
whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or
otherwise.
Contact:
KalVista Pharmaceuticals, Inc.
Leah Monteiro, Corporate Communications & Investor Relations
857-999-0808
lmm@KalVista.com
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Aug 2024 to Sep 2024
KalVista Pharmaceuticals (NASDAQ:KALV)
Historical Stock Chart
From Sep 2023 to Sep 2024